Latanoprost Mylan

Latanoprost, the active ingredient in Latanoprost Mylan, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used to treat open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latanoprost Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog indicated for conditions that require reduction of intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces elevated eye pressure to prevent development of glaucoma. Secondary open‑angle glaucoma: provides intra‑ocular pressure control when caused by other ocular conditions.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length and density - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision - Mild ocular discomfort

Serious or Rare Side Effects: - Unexpected rise in intra‑ocular pressure - Uveitis or intra‑ocular inflammation - Corneal edema or swelling - Allergic reaction with swelling of eyelids or face

Before initiating therapy, clinicians should evaluate ocular health and monitor patients regularly.

Assess baseline intra‑ocular pressure: ensure appropriate starting value. Monitor iris color change: document any progressive darkening. Avoid use in active ocular inflammation: postpone treatment until resolved. Check for hypersensitivity to prostaglandin analogs: discontinue if reaction occurs. Pregnancy and lactation: use only if benefit outweighs risk, as safety data are limited. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents that affect intra‑ocular pressure.

Major Interactions (Avoid): - Other prostaglandin analog eye drops: additive IOP‑lowering effect may cause excessive pressure reduction. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): may diminish Latanoprost efficacy.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers: monitor IOP for additive pressure‑lowering. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Systemic NSAIDs: generally safe but observe for any change in ocular response.